Toggle Main Menu Toggle Search

Open Access padlockePrints

The feasibility of implementing a hospital deprescribing behaviour change intervention and undertaking trial processes: A mixed methods evaluation

Lookup NU author(s): Professor Miles WithamORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2025 The Authors.Background CompreHensive geriAtRician-led MEdication Review (CHARMER) is a behaviour change intervention designed to address the determinants of geriatricians and pharmacists deprescribing in hospital. CHARMER comprises a deprescribing action plan, deprescribing briefings, videos of successful deprescribing consultations, deprescribing case studies workshop and a deprescribing performance dashboard. This study aimed to evaluate the feasibility of undertaking a CHARMER definitive trial and inform primary outcome measure selection (90-day hospital readmission or patient quality of life (QoL)). Methods A two-arm purposive allocation feasibility study was undertaken in four hospitals (three intervention, one control). Intervention fidelity and acceptability, outcome data completeness and quality were evaluated alongside acceptability of data collection methods. The process evaluation explored these via interviews with staff and patients. Data were used to inform primary outcome measure selection. Results Eighteen geriatricians and pharmacists received the CHARMER intervention and 318 patients admitted to study wards were enrolled. 90-day hospital readmission data were available for 290 (91.2 %) patients. Sixty-six (20.8 %) were approached for consent to complete QoL measures; 25 (37.9 %) consented and 13 (52 %) completed at baseline and 90-day follow up. All intervention components were implemented with acceptable fidelity; hospitals were unfamiliar with implementing action plans and unclear who should be involved with implementing the dashboard, leading to delays. Conclusions The CHARMER intervention is feasible to implement and given the low patient consent rate, 90-day readmission rate is the most appropriate primary outcome measure. Minor refinements to guidance will facilitate hospitals to undertake activities for implementation that are unfamiliar. Clinical trial registration The study was registered on ISRCTN ( ISRCTN11899506 ).


Publication metadata

Author(s): Scott S, Martin-Kerry J, Pritchard M, Atkins B, Clark AB, Grant K, Alldred DP, Colles A, Hammond A, Murphy K, Keevil VL, Kellar I, Patel M, Sims E, Taylor J, Turner DA, Witham M, Wright D, Bhattacharya D

Publication type: Article

Publication status: Published

Journal: Research in Social and Administrative Pharmacy

Year: 2026

Volume: 22

Issue: 2

Pages: 333-339

Print publication date: 01/02/2026

Online publication date: 26/11/2025

Acceptance date: 25/11/2025

Date deposited: 13/01/2026

ISSN (print): 1551-7411

ISSN (electronic): 1934-8150

Publisher: Elsevier

URL: https://doi.org/10.1016/j.sapharm.2025.11.005

DOI: 10.1016/j.sapharm.2025.11.005

PubMed id: 41320568


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Applied Research stream (award ID PGfAR 200874)
National Institute for Health and Care Research (NIHR)
NIHR Exeter Biomedical Research Centre.
NIHR Newcastle Biomedical Research Centre
NIHR Newcastle Clinical Research Facility

Share